Literature DB >> 14645000

Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/beta-thalassemia patient.

Vichai Atichartakarn1, Suporn Chuncharunee, Pakorn Chandanamattha, Khanchit Likittanasombat, Katcharin Aryurachai.   

Abstract

Chronic transfusion of packed red blood cells, in addition to other ongoing treatment with warfarin, acetyl salicylic acid, desferrioxamine, and other supportive measures, was given to a splenectomized hemoglobin E/beta-thalassemia woman with pulmonary arterial hypertension (PHT). Serial measurements of plasma thrombin-antithrombin III complex (TAT) levels and right-sided cardiac catheterization were used to monitor changes after treatment. Reduction of plasma TAT levels from 7.5 to 3.8 microg/L (normal, 3 +/- 2.4 microg/L), pulmonary vascular resistance (PVR) from 553.8 to 238.6 dyne.sec.cm(-5) (normal, 67 +/- 30 dyne.sec.cm(-5)), and mean pulmonary arterial pressure from 51 to 32 mm Hg (normal, 9 to 19 mm Hg) occurred in tandem. Normalization of blood hypercoagulability as reflected in plasma TAT level by chronic blood transfusion was the likely basis for improvement of increased PVR, being secondary to thrombotic pulmonary arteriopathy and subsequently PHT.

Entities:  

Mesh:

Year:  2003        PMID: 14645000     DOI: 10.1182/blood-2003-09-3094

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia.

Authors:  A Phrommintikul; A Sukonthasarn; R Kanjanavanit; W Nawarawong
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

2.  Hemolysis-associated pulmonary hypertension in thalassemia.

Authors:  Claudia R Morris; Frans A Kuypers; Gregory J Kato; Lisa Lavrisha; Sandra Larkin; Titi Singer; Elliott P Vichinsky
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

3.  Platelet haemostatic properties in β-thalassaemia: the effect of blood transfusion.

Authors:  Alice Trinchero; Marina Marchetti; Cinzia Giaccherini; Carmen J Tartari; Laura Russo; Anna Falanga
Journal:  Blood Transfus       Date:  2016-10-04       Impact factor: 3.443

Review 4.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

5.  Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy.

Authors:  Sylvia T Singer; Frans Kuypers; Jeffery Fineman; Ginny Gildengorin; Sandra Larkin; Nancy Sweeters; Howard Rosenfeld; Gregory Kurio; Annie Higa; Michael Jeng; James Huang; Elliott P Vichinsky
Journal:  Ann Hematol       Date:  2014-02-28       Impact factor: 3.673

Review 6.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

Review 7.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

Review 8.  Pulmonary hypertension associated with thalassemia syndromes.

Authors:  Dustin R Fraidenburg; Roberto F Machado
Journal:  Ann N Y Acad Sci       Date:  2016-03-23       Impact factor: 5.691

Review 9.  How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders.

Authors:  Evans M Machogu; Roberto F Machado
Journal:  Blood       Date:  2018-09-11       Impact factor: 22.113

Review 10.  Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders.

Authors:  Claudia R Morris; Mark T Gladwin; Gregory J Kato
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.